Pershing Square co-led an oversubscribed $250 million Series D financing round for Precision Neuroscience. The Ackman Oxman Institute and other life sciences investors participated in the funding.
Precision Neuroscience has raised a total of $430 million since its founding in 2021. The company develops brain-computer interface (BCI) technology to treat catastrophic neurological conditions.
CEO Bill Ackman highlighted the investment as a move to support medical solutions for brain recovery. The round signals growing investor confidence in the emerging BCI healthcare and technology sector.